145 related articles for article (PubMed ID: 20084783)
1. A short outpatient hydration schedule for cisplatin administration.
Al Bahrani BJ; Moylan EJ; Forouzesh B; Della-Fiorentina SA; Goldrick AJ
Gulf J Oncolog; 2009 Jan; (5):30-6. PubMed ID: 20084783
[TBL] [Abstract][Full Text] [Related]
2. [Cisplatin administration for outpatients with short hydration of less than four hours].
Hata A; Katakami N; Masuda Y; Kaji R; Fujita S; Iwamori S; Horai A; Takatori K; Ose T; Kitajima N; Mifune Y; Fukae M
Gan To Kagaku Ryoho; 2012 Sep; 39(9):1385-8. PubMed ID: 22996774
[TBL] [Abstract][Full Text] [Related]
3. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity.
Dana R; Kachhwaha VS
Indian J Cancer; 1996 Dec; 33(4):168-70. PubMed ID: 9254992
[TBL] [Abstract][Full Text] [Related]
4. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors.
Lagrange JL; Médecin B; Etienne MC; Pivot X; Cassuto-Viguier E; Renée N; Thyss A; Ferrero JM; Otto J; François E; Milano G
Pharmacotherapy; 1997; 17(6):1246-53. PubMed ID: 9399607
[TBL] [Abstract][Full Text] [Related]
6. [Usefulness of oral rehydration solution for hydration in cancer chemotherapy: toward the application of outpatient chemotherapy with high-dose Cisplatin therapy-].
Sato J; Kudo K; Hino K; Takahashi K
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1471-6. PubMed ID: 21918344
[TBL] [Abstract][Full Text] [Related]
7. Safe, rapid administration of cisplatin in the outpatient clinic.
Brock J; Alberts DS
Cancer Treat Rep; 1986 Dec; 70(12):1409-14. PubMed ID: 3539327
[TBL] [Abstract][Full Text] [Related]
8. Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study.
Sakaida E; Iwasawa S; Kurimoto R; Ebata T; Imai C; Oku T; Sekine I; Tada Y; Tatsumi K; Takiguchi Y
Jpn J Clin Oncol; 2016 Apr; 46(4):370-7. PubMed ID: 26755829
[TBL] [Abstract][Full Text] [Related]
9. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
[TBL] [Abstract][Full Text] [Related]
10. How many cisplatin administration protocols does your department use?
Greystoke AP; Jodrell DI; Cheung M; Rivans I; Mackean MJ
Eur J Cancer Care (Engl); 2010 Jan; 19(1):80-90. PubMed ID: 19708939
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
13. [The protective effects of two hydration protocols against cisplatin nephrotoxicity].
Guo JH; Song ST; Xu ZL
Zhonghua Zhong Liu Za Zhi; 1994 Jan; 16(1):56-8. PubMed ID: 8033751
[TBL] [Abstract][Full Text] [Related]
14. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma.
Tiseo M; Martelli O; Mancuso A; Sormani MP; Bruzzi P; Di Salvia R; De Marinis F; Ardizzoni A
Tumori; 2007; 93(2):138-44. PubMed ID: 17557559
[TBL] [Abstract][Full Text] [Related]
15. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
16. [Feasibility of short volume hydration in patients with lung cancer treated with Cisplatin-containing chemotherapy].
Ohhara Y; Isobe H; Ito K; Fuke S; Kojima T; Saito H; Nishiura Y
Gan To Kagaku Ryoho; 2015 Jan; 42(1):57-61. PubMed ID: 25596680
[TBL] [Abstract][Full Text] [Related]
17. Comparison of cisplatin-induced nephrotoxicity when using conventional versus short hydration in gastric cancer-a retrospective study.
Aoyama T; Tsunoda T; Kato H; Hagino A; Furutani R; Ito K; Yoshioka H; Nakamura M; Hiraide M; Kawakami K; Kobayashi K; Suzuki K; Ichimura T; Yamaguchi K; Hama T
J Chemother; 2020 May; 32(3):144-150. PubMed ID: 31960769
[TBL] [Abstract][Full Text] [Related]
18. Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial.
Benoehr P; Krueth P; Bokemeyer C; Grenz A; Osswald H; Hartmann JT
J Am Soc Nephrol; 2005 Feb; 16(2):452-8. PubMed ID: 15590762
[TBL] [Abstract][Full Text] [Related]
19. Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit.
Puisset F; Bigay-Game L; Paludetto MN; Martel A; Perriat S; Rabeau A; Canonge JM; Mazieres J
Support Care Cancer; 2019 May; 27(5):1679-1686. PubMed ID: 30120556
[TBL] [Abstract][Full Text] [Related]
20. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]